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Dear Editor,
Based on the findings of the emblematic 
PARADIGM-HF study [1], the combination of 
sacubitril with valsartan emerged as a revolu-
tionary treatment in heart failure with reduced 
ejection fraction. Sacubitril is a newly introduced 
neprilysin (NEP) inhibitor (NI) whereas valsartan 
constitutes a classic angiotensin II receptor block-
er (AR). The combination of the two resulted in 
the prototype of ARNI. Liczek M and colleagues 
in their interesting article [2] envision the use of 
ARNI in patients with chronic obstructive pulmo-
nary disease (COPD), especially if they present 
with pulmonary hypertension. The argument 
is based on the potential immune-supressory, 
vasodilatory and bronchodilatory properties of 
brain natriuretic peptide which is deliberated, 
after its degradation by NEP is inhibited. We find 
the proposition of expanding the use of ARNI in 
COPD challenging, however we would propose 
a global view of NEP and its substrates before 
attempting their modulation in COPD.
NEP is an endopeptidase catalyzing among 
others the degradation of beta amyloid Ab (es-
pecially the subtypes Ab40 and Ab42), atrial natri-
uretic peptide (ANP), and various kinines. NEP 
and its substrates are implicated in lung function 
in a manner that assumes particular significance 
regarding patients with COPD. NEP protects lung 
vasculature from remodeling, especially under 
conditions of hypoxia-induced pulmonary hyper-
tension. NEP activity, as well as NEP expression 
are reduced in alveolar walls and distal vessels 
in COPD patients [3]. Endothelin-1 and bombe-
sin-like peptides are NEP substrates with potent 
proliferative and vasoconstrictive properties, 
while fibroblast growth factor-2 demonstrates 
angiogenic effects. Pro-inflammatory substrates, 
such as substance P, contribute to pulmonary 
vascular remodeling, showing the importance of 
their degradation by NEP. Depression of NEP in 
pulmonary artery smooth muscle cells results in 
increased migration and proliferation, in response 
to serum and platelet-derived growth factor [4]. 
Generally speaking, there is an inverse line be-
tween NEP and pulmonary vascular remodeling , 
and this mechanism should be considered when 
attempting NEP inhibition in COPD.
Bradykinin (BK) is a NEP substrate with 
known broncho-constrictive properties which 
impact the course of asthma and COPD. BK is 
involved in virus-induced inflammatory cell in-
flux and airway hyperactivity [5]. The biological 
actions of BK are mediated through B1 and B2 re-
ceptors. B1R are overexpressed during respiratory 
infections, during which an increase of BK activi-
ty results in plasma protein extravasation, smooth 
muscle contraction, release of growth factors 
and angiogenin from bronchial fibroblasts and 
finally bronchoconstriction [6]. Inhibiting NEP in 
patients with asthma and COPD, is expected to 
induce increased amounts of BK, creating skepti-
cism about their potential bronchial side-effects.
ANP was found to increase after the adminis-
tration of ARNI. ANP is a form of arrhythmogenic 
amyloid which accumulates in the heart atria of 
the elderly, facilitating the development of atrial 
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fibrillation. In senile human atrial appendage speci-
mens, ANP amyloid fibrils are found around vessels 
and adjacent to atrial muscle cells [7]. Patients with 
COPD are vulnerable to atrial arrhythmogenesis 
especially when hypoxia, hypercapnia, pulmonary 
hypertension, diastolic dysfunction of left ventri-
cle, oxidative stress and inflammation coexist [8]. 
ANP deposition in the atria further aggravates these 
processes, with ATP containing aggregation-prone 
regions acting as templates for amyloid fibril forma-
tion after protein structural rearrangement in the 
atria. Establishment of atrial fibrillation in COPD 
patients is an unwelcome risk factor, predisposing 
to severe cardiorespiratory derangement.
Ab is another amyloid, which as a substrate 
for NEP is increased after ARNI administration. 
Subtypes Ab40 and Ab42 are the main components 
of amyloid plaques in the brain of patients with 
Alzheimer’s disease (AD). Similarly, increased 
expression of Ab is encountered in the retina of 
patients with progressive loss of their vision, as 
well as various neoplasms, including lung cancer. 
AD is a severe neurodegenerative disease, very 
common in COPD patients, ranging from 37 to 
62% [9]. In the serum of these patients increased 
levels of Ab are found, even in the absence of 
apparent cognitive impairment, and they appear 
to be in a state of dynamic equilibrium with 
corresponding brain levels [10]. Transport of Ab 
from the brain to the lungs and vice versa has 
been demonstrated, given the disruption of the 
blood-brain barrier induced to the vascular wall 
by Ab. In conditions of hypoxia and respiratory 
infections, Ab fibril deposition in COPD lungs 
further increases, with concomitant elevated 
levels in the serum and reduced clearance from 
the brain. An imminent pulmonary dementia is 
then underway.
ARNI are a new category of hemodynamically 
acting drugs and their enthusiastic prescription in 
patients with heart failure may gradually displace 
other classic therapies. Heart failure, especially 
under the form of diastolic dysfunction, frequent-
ly coexists with COPD. In a comorbid heart-lung 
context, patients with COPD and pulmonary hy-
pertension may become ideal candidates for the 
prescription of NEP inhibitors, as Liczek et al.[2] 
suggest. In the meanwhile, the more we enrich 
our knowledge on NEP and its substrates, the 
more we will be able to offer efficient, safe and 
individualized therapies in patients with COPD.
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